Scholarlink

<p>Mugwort-allergic patients frequently experience severe respiratory allergies due to sensitization to the major allergen Art v 1, with allergen-specific immunotherapy (ASIT) as the only causal treatment to halt disease progression. This study evaluated the effects of subcutaneous (SCIT) and sublingual (SLIT) ASIT with purified recombinant Art v 1 (rArt v 1) in a murine model of mugwort pollen of asthma. BALB/c mice were sensitized with <i>Artemisia vulgaris</i> pollen extract and treated with either rArt v 1-based SCIT adjuvanted with Montanide ISA-51, rArt v 1-based SLIT, an extract-based commercial SLIT vaccine, or PBS. Both rArt v 1-based SCIT and SLIT improved lung pathology and reduced airway reactivity following allergen challenge, with rArt v 1-based SCIT inducing Th1-polarized immune responses marked by increased IFN-γ production and rArt v 1-specific IgG<sub>1</sub>/IgG<sub>2a</sub>, while SLIT induced stronger mucosal IgA responses. These findings highlight the therapeutic potential of rArt v 1-based ASIT for mugwort allergy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of rArt v 1-based sublingual and subcutaneous immunotherapy in a murine model of asthma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月2日

查看全文
  • Kairat Tabynov,
  • Elmira Tailakova,
  • Guliza Rakhmatullayeva,
  • Turlan Bolatbekov,
  • Yeow Hong Lim,
  • Gleb Fomin,
  • Meruert Babayeva,
  • Rudolf Valenta,
  • Kaissar Tabynov

摘要

Mugwort-allergic patients frequently experience severe respiratory allergies due to sensitization to the major allergen Art v 1, with allergen-specific immunotherapy (ASIT) as the only causal treatment to halt disease progression. This study evaluated the effects of subcutaneous (SCIT) and sublingual (SLIT) ASIT with purified recombinant Art v 1 (rArt v 1) in a murine model of mugwort pollen of asthma. BALB/c mice were sensitized with Artemisia vulgaris pollen extract and treated with either rArt v 1-based SCIT adjuvanted with Montanide ISA-51, rArt v 1-based SLIT, an extract-based commercial SLIT vaccine, or PBS. Both rArt v 1-based SCIT and SLIT improved lung pathology and reduced airway reactivity following allergen challenge, with rArt v 1-based SCIT inducing Th1-polarized immune responses marked by increased IFN-γ production and rArt v 1-specific IgG1/IgG2a, while SLIT induced stronger mucosal IgA responses. These findings highlight the therapeutic potential of rArt v 1-based ASIT for mugwort allergy.